Senti Biosciences Holdings, Inc. — Form 8-K Summary
Report date: October 27, 2026. This is an event filing, not a financial-period report.
Business context and material events
- The Board set October 30, 2026, as the record date for the previously announced distribution of contingent value rights (CVRs).
- The CVR distribution is connected with transactions under a merger agreement dated July 14, 2026. Those transactions closed on October 21, 2026.
- Director Edward Mathers notified the Board of his resignation on October 27, effective immediately. He also resigned from all Board committees on which he served.
Financial performance and liquidity
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating financial metrics, and no comparison with a prior period.
Outlook, contingencies, and items to verify
The filing identifies the CVRs as contingent but does not provide their value, payment conditions, or expected distribution date. It provides no financial guidance or additional risk discussion.
- Verify the CVR distribution terms, eligibility requirements, contingencies, and timing in the related transaction documents or subsequent disclosures.
- Confirm the effect, if any, of Mr. Mathers’s departure on Board committee composition.